NYSE · Healthcare
Zoetis Inc. (ZTS)
As-reported financials and recent SEC filings for Zoetis Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$9.47B
Net income
$2.67B
Net margin
28.2%
Diluted EPS
$6.02
ROE
78.3%
P/E (TTM)
13.0×
Market cap
$33.36B
Debt / equity
2.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Gross profit | $6.80B | $6.54B | $5.98B | $5.63B | $5.47B |
| Operating income | — | — | — | — | — |
| Net income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| Diluted EPS | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SD2026-05-28
View on EDGAR →42026-05-26
View on EDGAR →8-K2026-05-22
View on EDGAR →42026-05-21
View on EDGAR →8-K2026-05-20
View on EDGAR →42026-05-13
View on EDGAR →42026-05-13
View on EDGAR →42026-05-12
View on EDGAR →Go deeper on ZTS
Search Zoetis Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.